首页 > 最新文献

Current Cardiology Reviews最新文献

英文 中文
Emerging Strategies and Effective Prevention Measures for Investigating the Association Between Stroke and Sudden Cardiac Fatality. 调查中风与心脏猝死之间关系的新策略和有效预防措施。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X259676231222053709
H Nithesh Kumar, S Jeevanandham, M Shankar Ganesh, M Ashmi Sabana, P Manivasakam

Stroke-related cardiac death is a significant concern for patients with stroke and their healthcare providers. It is a complex and multifaceted condition that requires careful management of both modifiable and non-modifiable risk factors. This review provides an overview of the pathophysiology, risk factors, and prevention strategies for stroke-related cardiac death. The review highlights the importance of identifying and managing modifiable risk factors such as hypertension, diabetes, and lifestyle factors, as well as non-modifiable risk factors such as age and genetics. Additionally, the review explores emerging strategies for prevention, including the use of wearable devices and genetic testing to identify patients at risk, stem cell therapy and gene therapy for cardiac dysfunction, and precision medicine for personalized treatment plans. Despite some limitations to this review, it provides valuable insights into the current understanding of stroke-related cardiac death and identifies important areas for future research. Ultimately, the implementation of evidence-based prevention strategies and personalized treatment plans has the potential to improve outcomes for patients with stroke and reduce the burden of stroke-related cardiac death in the population.

脑卒中相关心源性死亡是脑卒中患者及其医疗服务提供者非常关注的问题。它是一种复杂的、多方面的疾病,需要对可改变和不可改变的风险因素进行谨慎管理。本综述概述了卒中相关心源性死亡的病理生理学、风险因素和预防策略。综述强调了识别和管理可改变的风险因素(如高血压、糖尿病和生活方式因素)以及不可改变的风险因素(如年龄和遗传)的重要性。此外,综述还探讨了新出现的预防策略,包括使用可穿戴设备和基因检测来识别高危患者、干细胞疗法和基因疗法治疗心脏功能障碍,以及精准医学的个性化治疗方案。尽管本综述存在一些局限性,但它为人们目前对中风相关心脏死亡的了解提供了宝贵的见解,并确定了未来研究的重要领域。最终,循证预防策略和个性化治疗方案的实施有可能改善中风患者的预后,并减轻人群中中风相关心源性死亡的负担。
{"title":"Emerging Strategies and Effective Prevention Measures for Investigating the Association Between Stroke and Sudden Cardiac Fatality.","authors":"H Nithesh Kumar, S Jeevanandham, M Shankar Ganesh, M Ashmi Sabana, P Manivasakam","doi":"10.2174/011573403X259676231222053709","DOIUrl":"10.2174/011573403X259676231222053709","url":null,"abstract":"<p><p>Stroke-related cardiac death is a significant concern for patients with stroke and their healthcare providers. It is a complex and multifaceted condition that requires careful management of both modifiable and non-modifiable risk factors. This review provides an overview of the pathophysiology, risk factors, and prevention strategies for stroke-related cardiac death. The review highlights the importance of identifying and managing modifiable risk factors such as hypertension, diabetes, and lifestyle factors, as well as non-modifiable risk factors such as age and genetics. Additionally, the review explores emerging strategies for prevention, including the use of wearable devices and genetic testing to identify patients at risk, stem cell therapy and gene therapy for cardiac dysfunction, and precision medicine for personalized treatment plans. Despite some limitations to this review, it provides valuable insights into the current understanding of stroke-related cardiac death and identifies important areas for future research. Ultimately, the implementation of evidence-based prevention strategies and personalized treatment plans has the potential to improve outcomes for patients with stroke and reduce the burden of stroke-related cardiac death in the population.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"35-44"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Timing of Surgery for Asymptomatic Primary Mitral Regurgitation: Possible Value of Early, Serial Measurements of Left Ventricular Sphericity. 无症状原发性二尖瓣反流的手术时机:早期连续测量左心室球形度的可能价值。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X277223240206062319
Alfred Stanley, Constantine Athanasuleas

Asymptomatic primary mitral regurgitation due to myxomatous degeneration of the mitral valve leaflets may remain so for long periods, even as left ventricular function progresses to a decompensated stage. During the early compensated stage, the ventricle's initial response to the volume overload is an asymmetric increase in the diastolic short axis dimension, accomplished by a diastolic shift of the interventricular septum into the right ventricular cavity, creating a more spherical left ventricular diastolic shape, increasing diastolic filling and stroke volume. Early valve repair is recommended to reduce postoperative left ventricular dysfunction. Early serial measurements of left ventricular sphericity index [LV-Si]. during the compensated stage of mitral regurgitation might identify subtle changes in left ventricular shape and assist in determining the optimal earliest timing for surgical intervention.

由于二尖瓣瓣叶肌瘤变性而导致的无症状原发性二尖瓣反流可能会长期存在,即使左心室功能发展到失代偿阶段也是如此。在早期代偿阶段,心室对容量超负荷的最初反应是舒张短轴尺寸的非对称增加,通过室间隔向右心室腔的舒张期移位来实现,从而使左心室的舒张期形状更加球形,增加舒张期充盈和每搏容量。建议尽早进行瓣膜修复,以减少术后左心室功能障碍。在二尖瓣反流的代偿期,早期连续测量左心室球形指数(LV-Si)可能会发现左心室形态的细微变化,并有助于确定手术干预的最佳最早时机。
{"title":"Timing of Surgery for Asymptomatic Primary Mitral Regurgitation: Possible Value of Early, Serial Measurements of Left Ventricular Sphericity.","authors":"Alfred Stanley, Constantine Athanasuleas","doi":"10.2174/011573403X277223240206062319","DOIUrl":"10.2174/011573403X277223240206062319","url":null,"abstract":"<p><p>Asymptomatic primary mitral regurgitation due to myxomatous degeneration of the mitral valve leaflets may remain so for long periods, even as left ventricular function progresses to a decompensated stage. During the early compensated stage, the ventricle's initial response to the volume overload is an asymmetric increase in the diastolic short axis dimension, accomplished by a diastolic shift of the interventricular septum into the right ventricular cavity, creating a more spherical left ventricular diastolic shape, increasing diastolic filling and stroke volume. Early valve repair is recommended to reduce postoperative left ventricular dysfunction. Early serial measurements of left ventricular sphericity index [LV-Si]. during the compensated stage of mitral regurgitation might identify subtle changes in left ventricular shape and assist in determining the optimal earliest timing for surgical intervention.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"93-101"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Reflexes - Vagus as the Key Player. 心血管反射--迷走神经是关键角色。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X284831240408053528
Shantala S Herlekar, Ashwini R Doyizode, Savitri P Siddangoudra, V Anupama

The cardiac and vascular systems work in coordination by activating various reflex mechanisms based on the body's needs. These may be during physiological variations or pathophysiological changes seen in disease conditions of varying degrees of severity. This article intends to explain various reflexes involved in the homeostasis of the cardiovascular system and the role of vagus as the key component in all these reflexes. The article also explains the components of the reflex arc, the stimulus and response, and the role of reflex in a few diseases. This article describes 22 different cardiovascular reflexes in detail.

心脏和血管系统根据身体需要启动各种反射机制,从而协调工作。这可能是在生理变化期间,也可能是在不同程度的疾病情况下出现的病理生理变化。本文旨在解释心血管系统平衡所涉及的各种反射,以及迷走神经作为所有这些反射的关键组成部分所起的作用。文章还解释了反射弧的组成部分、刺激和反应以及反射在一些疾病中的作用。本文详细介绍了 22 种不同的心血管反射。
{"title":"Cardiovascular Reflexes - Vagus as the Key Player.","authors":"Shantala S Herlekar, Ashwini R Doyizode, Savitri P Siddangoudra, V Anupama","doi":"10.2174/011573403X284831240408053528","DOIUrl":"10.2174/011573403X284831240408053528","url":null,"abstract":"<p><p>The cardiac and vascular systems work in coordination by activating various reflex mechanisms based on the body's needs. These may be during physiological variations or pathophysiological changes seen in disease conditions of varying degrees of severity. This article intends to explain various reflexes involved in the homeostasis of the cardiovascular system and the role of vagus as the key component in all these reflexes. The article also explains the components of the reflex arc, the stimulus and response, and the role of reflex in a few diseases. This article describes 22 different cardiovascular reflexes in detail.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e290424229476"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140849834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis. 血清花粉素样蛋白与心血管疾病的关系:系统回顾与元分析》。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X304195240715103930
Amir Mahmoud Ahmadzadeh, Rozita Khodashahi, Mahmoud Mohamadzadeh Shabestari, Mohsen Aliakbarian, Amirhossein Sahebkar, Mohammad-Hassan Arjmand

Background: Follistatin-like proteins (FSTLs) are adipomyokines secreted by adipocytes and myocytes. Previous studies have reported an increase in circulating FSTL1 levels in response to cardiovascular injuries. In this study, we conducted a systematic review and metaanalysis to assess the association between circulating FSTLs and Cardiovascular Diseases (CVDs).

Methods: We performed a comprehensive literature search using PubMed, Web of Science, Scopus, and Embase databases. After screening the articles, we selected eligible studies, extracted relevant data, and calculated the pooled Standardized Mean Difference (SMD). We also conducted a sensitivity analysis to identify sources of heterogeneity and assessed publication bias.

Results: Among the 577 articles initially retrieved, we included 5 studies comprising a total of 941 cases with CVDs and 446 controls. All included studies measured FSTL1 levels. The pooled SMD analysis revealed a significant difference in circulating FSTL1 levels between subjects with CVDs and control groups (SMD = 0.853, 95% CI = 0.158-1.548, P = 0.016). Heterogeneity was primarily attributed to a single study that measured FSTL1 levels in heart failure patients with preserved ejection fraction. No publication bias was observed.

Conclusion: Our findings demonstrate significantly higher levels of FSTL1 in patients with CVD compared to control subjects. This suggests that FSTL1 may have potential as a diagnostic and prognostic biomarker in CVDs. However, further well-designed studies are needed to validate its clinical utility.

背景:类软骨素蛋白(FSTLs)是由脂肪细胞和肌细胞分泌的脂肪肌动素。先前的研究报告称,心血管损伤时,循环中的 FSTL1 水平会升高。在本研究中,我们进行了一项系统回顾和荟萃分析,以评估循环 FSTLs 与心血管疾病(CVDs)之间的关联:我们使用 PubMed、Web of Science、Scopus 和 Embase 数据库进行了全面的文献检索。在对文章进行筛选后,我们选出了符合条件的研究,提取了相关数据,并计算了汇总的标准化平均差(SMD)。我们还进行了敏感性分析,以确定异质性的来源并评估发表偏倚:在最初检索到的 577 篇文章中,我们纳入了 5 项研究,共包括 941 例心血管疾病患者和 446 例对照者。所有纳入的研究都测量了FSTL1水平。汇总的SMD分析显示,心血管疾病患者和对照组之间的循环FSTL1水平存在显著差异(SMD = 0.853, 95% CI = 0.158-1.548, P = 0.016)。异质性主要归因于一项测量射血分数保留的心衰患者FSTL1水平的研究。未发现发表偏倚:我们的研究结果表明,与对照组相比,心血管疾病患者的 FSTL1 水平明显更高。这表明 FSTL1 有可能成为心血管疾病的诊断和预后生物标志物。不过,还需要进一步设计完善的研究来验证其临床实用性。
{"title":"The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis.","authors":"Amir Mahmoud Ahmadzadeh, Rozita Khodashahi, Mahmoud Mohamadzadeh Shabestari, Mohsen Aliakbarian, Amirhossein Sahebkar, Mohammad-Hassan Arjmand","doi":"10.2174/011573403X304195240715103930","DOIUrl":"10.2174/011573403X304195240715103930","url":null,"abstract":"<p><strong>Background: </strong>Follistatin-like proteins (FSTLs) are adipomyokines secreted by adipocytes and myocytes. Previous studies have reported an increase in circulating FSTL1 levels in response to cardiovascular injuries. In this study, we conducted a systematic review and metaanalysis to assess the association between circulating FSTLs and Cardiovascular Diseases (CVDs).</p><p><strong>Methods: </strong>We performed a comprehensive literature search using PubMed, Web of Science, Scopus, and Embase databases. After screening the articles, we selected eligible studies, extracted relevant data, and calculated the pooled Standardized Mean Difference (SMD). We also conducted a sensitivity analysis to identify sources of heterogeneity and assessed publication bias.</p><p><strong>Results: </strong>Among the 577 articles initially retrieved, we included 5 studies comprising a total of 941 cases with CVDs and 446 controls. All included studies measured FSTL1 levels. The pooled SMD analysis revealed a significant difference in circulating FSTL1 levels between subjects with CVDs and control groups (SMD = 0.853, 95% CI = 0.158-1.548, P = 0.016). Heterogeneity was primarily attributed to a single study that measured FSTL1 levels in heart failure patients with preserved ejection fraction. No publication bias was observed.</p><p><strong>Conclusion: </strong>Our findings demonstrate significantly higher levels of FSTL1 in patients with CVD compared to control subjects. This suggests that FSTL1 may have potential as a diagnostic and prognostic biomarker in CVDs. However, further well-designed studies are needed to validate its clinical utility.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e180724231994"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Plants in the Treatment of Myocardial Infarction Disease: A Systematic Review. 治疗心肌梗塞疾病的药用植物:系统综述。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X278881240405044328
Anamika Rathore, Anuj Kumar Sharma, Yogesh Murti, Sonal Bansal, Vibha Kumari, Varsha Snehi, Mayank Kulshreshtha

Background: Myocardial infarction (MI), also referred to as a "heart attack," is brought on by a partial or total interruption of blood supply to the myocardium. Myocardial infarction can be "silent," go undiagnosed, or it can be a catastrophic occurrence that results in hemodynamic decline and untimely death. In recent years, herbal remedies for MI have become effective, secure, and readily accessible.

Objective: The purpose of this review was to examine the medicinal plants and phytochemicals that have been used to treat MI in order to assess the potential contribution of natural substances to the development of herbal MI treatments.

Methodology: A literature search was employed to find information utilizing electronic databases, such as Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane.

Results: The identification of 140 plants from 12 families led to the abstraction of data on the plant families, parts of the plant employed, chemical contents, extracts, model used, and dose.

Conclusion: The majority of the MI plants, according to the data, belonged to the Fabaceae (11%) and Asteraceae (9%) families, and the most prevalent natural components in plants with MI were flavonoids (43%), glucosides (25%), alkaloids (23%), phenolic acid (19%), saponins (15%), and tannins (12%).

背景:心肌梗塞(MI)又称 "心脏病发作",是由心肌供血部分或全部中断引起的。心肌梗塞可能是 "无声的",不会被诊断出来,也可能是灾难性的,导致血液动力学衰退和过早死亡。近年来,治疗心肌梗死的草药疗法变得有效、安全且容易获得:本综述旨在研究用于治疗心肌梗死的药用植物和植物化学物质,以评估天然物质对开发心肌梗死草药疗法的潜在贡献:方法:采用文献检索法,利用 Web of Science、Google Scholar、PubMed、Sci Finder、Reaxys 和 Cochrane 等电子数据库查找信息:结果:通过对 12 个科 140 种植物的鉴定,抽取了有关植物科、使用部分、化学成分、提取物、使用模式和剂量的数据:数据显示,大多数有MI的植物属于豆科(11%)和菊科(9%),有MI的植物中最常见的天然成分是黄酮类(43%)、苷类(25%)、生物碱类(23%)、酚酸类(19%)、皂苷类(15%)和单宁酸类(12%)。
{"title":"Medicinal Plants in the Treatment of Myocardial Infarction Disease: A Systematic Review.","authors":"Anamika Rathore, Anuj Kumar Sharma, Yogesh Murti, Sonal Bansal, Vibha Kumari, Varsha Snehi, Mayank Kulshreshtha","doi":"10.2174/011573403X278881240405044328","DOIUrl":"10.2174/011573403X278881240405044328","url":null,"abstract":"<p><strong>Background: </strong>Myocardial infarction (MI), also referred to as a \"heart attack,\" is brought on by a partial or total interruption of blood supply to the myocardium. Myocardial infarction can be \"silent,\" go undiagnosed, or it can be a catastrophic occurrence that results in hemodynamic decline and untimely death. In recent years, herbal remedies for MI have become effective, secure, and readily accessible.</p><p><strong>Objective: </strong>The purpose of this review was to examine the medicinal plants and phytochemicals that have been used to treat MI in order to assess the potential contribution of natural substances to the development of herbal MI treatments.</p><p><strong>Methodology: </strong>A literature search was employed to find information utilizing electronic databases, such as Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane.</p><p><strong>Results: </strong>The identification of 140 plants from 12 families led to the abstraction of data on the plant families, parts of the plant employed, chemical contents, extracts, model used, and dose.</p><p><strong>Conclusion: </strong>The majority of the MI plants, according to the data, belonged to the Fabaceae (11%) and Asteraceae (9%) families, and the most prevalent natural components in plants with MI were flavonoids (43%), glucosides (25%), alkaloids (23%), phenolic acid (19%), saponins (15%), and tannins (12%).</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e290424229484"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuchal Translucency and Congenital Heart Defects. 颈部透明带与先天性心脏缺陷
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X264963231128045500
A Sofia-Gonçalves, L Guedes-Martins

Nuchal translucency comprises a temporary accumulation of fluid in the subcutaneous tissue on the back of a fetus's neck, which accompanies the crown-rump length and is observed through an ultrasound performed between 11 and 13 weeks + 6 days gestation. Nuchal translucency is considered to be above normal when values are higher than the 95th/99th percentile or equal to or higher than 2.5/3.5 mm. The first connection between increased nuchal translucency and the presence of congenital heart defects is described in the study of Hyett et al., who observed that they are directly proportional. Since that time, several studies have been conducted to understand if nuchal translucency measurements can be used for congenital heart defect screening in euploid fetuses. However, there is great variability in the estimated nuchal translucency cutoff values for congenital heart defect detection. The purpose of this review was to understand how increased nuchal translucency values and congenital heart defects are related and to identify which of these defects are more frequently associated with an increase in these values.

頸項透明層是指胎兒頸部皮下組織暫時積聚的液體,與頭臀長度同時出現,在妊娠 11 至 13 週 +6 天之間進行超聲波檢查時可觀察到。当颈项透明层的数值高于第 95/99 百分位数或等于或高于 2.5/3.5 毫米时,就被认为是高于正常值。Hyett 等人的研究首次描述了颈部透明带增加与先天性心脏缺损之间的联系,他们发现两者成正比。从那时起,已经开展了多项研究,以了解颈项透明带测量值是否可用于优倍体胎儿的先天性心脏缺陷筛查。然而,用于先天性心脏缺陷检测的估计颈项透明 度临界值存在很大差异。本综述的目的是了解颈部透明带值的增加与先天性心脏缺损的关系,并确定哪些先天性心脏缺损与颈部透明带值的增加更常见。
{"title":"Nuchal Translucency and Congenital Heart Defects.","authors":"A Sofia-Gonçalves, L Guedes-Martins","doi":"10.2174/011573403X264963231128045500","DOIUrl":"10.2174/011573403X264963231128045500","url":null,"abstract":"<p><p>Nuchal translucency comprises a temporary accumulation of fluid in the subcutaneous tissue on the back of a fetus's neck, which accompanies the <i>crown-rump length</i> and is observed through an ultrasound performed between 11 and 13 weeks + 6 days gestation. Nuchal translucency is considered to be above normal when values are higher than the 95th/99th percentile or equal to or higher than 2.5/3.5 mm. The first connection between increased nuchal translucency and the presence of congenital heart defects is described in the study of <i>Hyett et al</i>., who observed that they are directly proportional. Since that time, several studies have been conducted to understand if nuchal translucency measurements can be used for congenital heart defect screening in euploid fetuses. However, there is great variability in the estimated nuchal translucency cutoff values for congenital heart defect detection. The purpose of this review was to understand how increased nuchal translucency values and congenital heart defects are related and to identify which of these defects are more frequently associated with an increase in these values.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary Effects of Fasting on the Lipid Panel. 禁食对血脂组合的饮食影响
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X257173231222042846
Jason Hourizadeh, Rezwan Munshi, Roman Zeltser, Amgad N Makaryus

Introduction: Dietary habits, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH), have been shown to improve cardiac health. Another more recent popular form of dieting incorporates periods of fasting known as intermittent fasting. The two main forms are alternate-day fasting and time-restricted eating.

Methods: PubMed search and literature review was undertaken. This review evaluates the current literature regarding the effects of the fasting dietary model and other types of fasting upon the lipid panel.

Results: There have been studies that have shown that intermittent fasting does provide a benefit in cardiovascular health, weight loss, and hypertension. However, the effect on cholesterol and triglyceride levels during intermittent fasting is in question.

Conclusion: The effect that fasting has on one's lipid panel is unclear, there are studies that show that different forms of fasting affect the lipid panel in various ways. There are studies that show that intermittent fasting does improve one's lipid profile and provides health benefits. Randomized controlled clinical trials with a large sample size are needed to evaluate the effects that intermittent fasting has based on race, ethnicity, gender, obesity, dyslipidemia, diabetic and healthy patients, and will lead to definitive evidence of lipid panel outcomes beyond current evidence based solely upon observational cohorts with numerous and multifactorial confounding factors and biases.

导言:地中海饮食和高血压饮食疗法(DASH)等饮食习惯已被证明可改善心脏健康:方法:最近流行的另一种节食方式是禁食,即间歇性禁食。主要有隔日禁食和限时进食两种形式:结果:有研究表明,间歇性禁食确实对心血管健康、减肥和高血压有好处。然而,间歇性禁食对胆固醇和甘油三酯水平的影响还存在疑问:本综述评估了有关这种饮食模式和其他类型的禁食对血脂组合影响的现有文献。
{"title":"Dietary Effects of Fasting on the Lipid Panel.","authors":"Jason Hourizadeh, Rezwan Munshi, Roman Zeltser, Amgad N Makaryus","doi":"10.2174/011573403X257173231222042846","DOIUrl":"10.2174/011573403X257173231222042846","url":null,"abstract":"<p><strong>Introduction: </strong>Dietary habits, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH), have been shown to improve cardiac health. Another more recent popular form of dieting incorporates periods of fasting known as intermittent fasting. The two main forms are alternate-day fasting and time-restricted eating.</p><p><strong>Methods: </strong>PubMed search and literature review was undertaken. This review evaluates the current literature regarding the effects of the fasting dietary model and other types of fasting upon the lipid panel.</p><p><strong>Results: </strong>There have been studies that have shown that intermittent fasting does provide a benefit in cardiovascular health, weight loss, and hypertension. However, the effect on cholesterol and triglyceride levels during intermittent fasting is in question.</p><p><strong>Conclusion: </strong>The effect that fasting has on one's lipid panel is unclear, there are studies that show that different forms of fasting affect the lipid panel in various ways. There are studies that show that intermittent fasting does improve one's lipid profile and provides health benefits. Randomized controlled clinical trials with a large sample size are needed to evaluate the effects that intermittent fasting has based on race, ethnicity, gender, obesity, dyslipidemia, diabetic and healthy patients, and will lead to definitive evidence of lipid panel outcomes beyond current evidence based solely upon observational cohorts with numerous and multifactorial confounding factors and biases.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"82-92"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting Waist Circumference: A Hypertension Risk Factor that Requires a More In-depth Understanding. 重新审视腰围:需要更深入了解的高血压风险因素。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X290574240322041356
Yue Su, Jin-Yu Sun, Zhen-Yang Su, Wei Sun

As a major cause of various cardiovascular diseases, the prevalence of hypertension has been increasing in the past 30 years, leading to significant socioeconomic and health burdens. Obesity is one of the major risk factors for hypertension. Body mass index (BMI) is the most used anthropometric index to measure obesity in clinical practice and to assess the risk of obesity-related diseases. However, obesity is a heterogeneous disease, and the accumulation of fat in different body regions leads to differences in cardiovascular and metabolic risks. BMI only reflects the overall obesity but does not consider the distribution of fat and muscle mass. The limitation of BMI makes it insufficient to assess the risk of hypertension attributed to obesity. In addition, waist circumference is an easily obtainable anthropometric index to evaluate abdominal fat distribution. High waist circumference is an independent risk factor for various cardiovascular diseases and all-cause mortality regardless of BMI. Preliminary data indicate that waist circumference is significantly associated with the risk of hypertension at different BMI levels. However, routine measurement of waist circumference is currently not required in current clinical guidelines or is only recommended for obese populations, indicating an insufficient understanding of waist circumference. In this review, we summarize the measurement methods and diagnostic thresholds of waist circumference for abdominal obesity, the trend of central obesity prevalence, the superiority of waist circumference over other anthropometric indices, and recent cross-sectional and longitudinal studies on the association between obesity and hypertension.

作为各种心血管疾病的主要诱因,高血压的发病率在过去 30 年里不断上升,造成了巨大的社会经济和健康负担。肥胖是高血压的主要风险因素之一。体重指数(BMI)是临床上测量肥胖和评估肥胖相关疾病风险最常用的人体测量指数。然而,肥胖是一种异质性疾病,不同身体区域的脂肪堆积会导致心血管和代谢风险的差异。体重指数只能反映总体肥胖程度,但不考虑脂肪和肌肉质量的分布。体重指数的局限性使其不足以评估肥胖导致的高血压风险。此外,腰围是一种易于获得的人体测量指标,可用于评估腹部脂肪分布。高腰围是各种心血管疾病和全因死亡率的独立风险因素,与体重指数无关。初步数据表明,在不同的体重指数水平下,腰围与高血压的风险显著相关。然而,目前的临床指南并未要求对腰围进行常规测量,或仅建议肥胖人群进行测量,这表明人们对腰围的认识还不够充分。在这篇综述中,我们总结了腹型肥胖腰围的测量方法和诊断阈值、中心性肥胖的流行趋势、腰围相对于其他人体测量指数的优越性,以及最近关于肥胖与高血压之间关系的横断面和纵向研究。
{"title":"Revisiting Waist Circumference: A Hypertension Risk Factor that Requires a More In-depth Understanding.","authors":"Yue Su, Jin-Yu Sun, Zhen-Yang Su, Wei Sun","doi":"10.2174/011573403X290574240322041356","DOIUrl":"10.2174/011573403X290574240322041356","url":null,"abstract":"<p><p>As a major cause of various cardiovascular diseases, the prevalence of hypertension has been increasing in the past 30 years, leading to significant socioeconomic and health burdens. Obesity is one of the major risk factors for hypertension. Body mass index (BMI) is the most used anthropometric index to measure obesity in clinical practice and to assess the risk of obesity-related diseases. However, obesity is a heterogeneous disease, and the accumulation of fat in different body regions leads to differences in cardiovascular and metabolic risks. BMI only reflects the overall obesity but does not consider the distribution of fat and muscle mass. The limitation of BMI makes it insufficient to assess the risk of hypertension attributed to obesity. In addition, waist circumference is an easily obtainable anthropometric index to evaluate abdominal fat distribution. High waist circumference is an independent risk factor for various cardiovascular diseases and all-cause mortality regardless of BMI. Preliminary data indicate that waist circumference is significantly associated with the risk of hypertension at different BMI levels. However, routine measurement of waist circumference is currently not required in current clinical guidelines or is only recommended for obese populations, indicating an insufficient understanding of waist circumference. In this review, we summarize the measurement methods and diagnostic thresholds of waist circumference for abdominal obesity, the trend of central obesity prevalence, the superiority of waist circumference over other anthropometric indices, and recent cross-sectional and longitudinal studies on the association between obesity and hypertension.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e270324228382"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cross Talks between CNS and CVS Diseases: An Alliance to Annihilate. 中枢神经系统疾病与慢性阻塞性肺疾病之间的交叉对话:消灭联盟
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X278550240221112636
Shivani Chib, Sushma Devi, Rishabh Chalotra, Neeraj Mittal, Thakur Gurjeet Singh, Puneet Kumar, Randhir Singh

Cardiovascular and neurological diseases cause substantial morbidity and mortality globally. Moreover, cardiovascular diseases are the leading cause of death globally. About 17.9 million people are affected by cardiovascular diseases and 6.8 million people die every year due to neurological diseases. The common neurologic manifestations of cardiovascular illness include stroke syndrome which is responsible for unconsciousness and several other morbidities significantly diminished the quality of life of patients. Therefore, it is prudent need to explore the mechanistic and molecular connection between cardiovascular disorders and neurological disorders. The present review emphasizes the association between cardiovascular and neurological diseases specifically Parkinson's disease, Alzheimer's disease, and Huntington's disease.

心血管和神经系统疾病在全球范围内造成大量的发病率和死亡率。此外,心血管疾病是全球死亡的主要原因。每年约有 1790 万人受到心血管疾病的影响,680 万人死于神经系统疾病。心血管疾病常见的神经系统表现包括中风综合征,这种疾病会导致患者昏迷不醒,并引发其他一些病症,大大降低了患者的生活质量。因此,探索心血管疾病与神经系统疾病之间的机理和分子联系是非常必要的。本综述强调了心血管疾病与神经系统疾病(尤其是帕金森病、阿尔茨海默病和亨廷顿病)之间的联系。
{"title":"Cross Talks between CNS and CVS Diseases: An Alliance to Annihilate.","authors":"Shivani Chib, Sushma Devi, Rishabh Chalotra, Neeraj Mittal, Thakur Gurjeet Singh, Puneet Kumar, Randhir Singh","doi":"10.2174/011573403X278550240221112636","DOIUrl":"10.2174/011573403X278550240221112636","url":null,"abstract":"<p><p>Cardiovascular and neurological diseases cause substantial morbidity and mortality globally. Moreover, cardiovascular diseases are the leading cause of death globally. About 17.9 million people are affected by cardiovascular diseases and 6.8 million people die every year due to neurological diseases. The common neurologic manifestations of cardiovascular illness include stroke syndrome which is responsible for unconsciousness and several other morbidities significantly diminished the quality of life of patients. Therefore, it is prudent need to explore the mechanistic and molecular connection between cardiovascular disorders and neurological disorders. The present review emphasizes the association between cardiovascular and neurological diseases specifically Parkinson's disease, Alzheimer's disease, and Huntington's disease.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"63-76"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review of Herbal Interventions for the Management of Cardiovascular Diseases. 草药干预治疗心血管疾病的系统回顾。
IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.2174/011573403X286573240422104647
Ankita Wal, Neha Verma, Senthil Kumar Balakrishnan, Vinod Gahlot, Sumeet Dwivedi, Pankaj Kumar Sahu, Mohammad Tabish, Pranay Wal

Background: Cardiovascular diseases represent a significant global health burden, necessitating diverse approaches for effective management. Herbal interventions have gained attention as potential adjuncts or alternatives to conventional therapies due to their perceived safety and therapeutic potential. This structured abstract provides a comprehensive review of herbal interventions for the management of CVDs, summarising key findings, mechanisms of action, and clinical implications.

Objective: This systematic review aims to evaluate the impact of various herbal interventions employed for managing cardiovascular diseases.

Method: We conducted an extensive literature search across electronic databases, including PubMed, Scopus, and Web of Science, from inception to 2022. Studies were included if they investigated the use of herbal remedies for preventing or treating CVDs. Data extraction and synthesis focused on botanical sources, active compounds, mechanisms of action, and clinical outcomes.

Result: Numerous herbal interventions have demonstrated promising cardiovascular benefits. A number of medicinal herbs well identified to treat CVD are Moringaoleifera, Ginseng, Ginkgo biloba, Celosia argentea, Gongronematrifolium, Gynostemmapentaphyllum, Bombaxceiba, Gentianalutea, Allium sativum, Crataegus spp, Curcuma longa, Camellia sinensis, and Zingiber officinale. Mechanistic insights reveal that herbal interventions often target multiple pathways involved in CVD pathogenesis. These mechanisms encompass anti-inflammatory, antioxidant, anti-thrombotic, anti-hypertensive, and lipid-lowering effects. Additionally, some herbs enhance endothelial function, promote nitric oxide production, and exert vasodilatory effects, contributing to improved cardiovascular health. Clinical studies have provided evidence of the efficacy of certain herbal interventions in reducing CVD risk factors and improving patient outcomes. However, more rigorous, large-scale clinical trials are needed to establish their long-term safety and effectiveness. It is crucial to consider potential herb-drug interactions and standardise dosages for reliable therapeutic outcomes.

Conclusion: This comprehensive review highlights the potential of herbal interventions as valuable adjuncts or alternatives for managing cardiovascular diseases. Herbal remedies offer diverse mechanisms of action, targeting key CVD risk factors and pathways. While promising, their clinical utility warrants further investigation through well-designed trials to establish their safety and efficacy, paving the way for integrated approaches to cardiovascular disease management. Healthcare providers and patients should engage in informed discussions about the use of herbal interventions alongside conventional therapies in the context of CVD prevention and treatment.

背景:心血管疾病给全球健康带来了沉重负担,需要采取多种方法进行有效治疗。草药干预作为传统疗法的潜在辅助或替代疗法,因其安全性和治疗潜力而备受关注。本结构式摘要全面综述了治疗心血管疾病的草药干预措施,总结了主要发现、作用机制和临床意义:本系统综述旨在评估用于治疗心血管疾病的各种草药干预措施的影响:我们在电子数据库(包括 PubMed、Scopus 和 Web of Science)中进行了广泛的文献检索,时间跨度从开始到 2022 年。凡是调查使用草药预防或治疗心血管疾病的研究均被纳入。数据提取和综合侧重于植物来源、活性化合物、作用机制和临床结果:结果:许多草药干预措施已证明对心血管有益。经确认可治疗心血管疾病的草药有:Moringaoleifera、人参、银杏叶、青葙子、Gongronematrifolium、Gynostemmapentaphyllum、Bombaxceiba、Gentianalutea、Allium sativum、Crataegusspp、Curcuma longa、Camellia sinensis 和 Zingiberofficinale。机理研究表明,草药干预通常针对心血管疾病发病机制中的多种途径。这些机制包括抗炎、抗氧化、抗血栓、抗高血压和降血脂作用。此外,一些草药还能增强内皮功能,促进一氧化氮的产生,发挥扩张血管的作用,有助于改善心血管健康。临床研究证明,某些草药干预措施在降低心血管疾病风险因素和改善患者预后方面具有疗效。然而,还需要更严格的大规模临床试验来确定其长期安全性和有效性。关键是要考虑到草药与药物之间潜在的相互作用,并规范剂量,以获得可靠的治疗效果:本综述强调了草药干预作为治疗心血管疾病的重要辅助手段或替代方法的潜力。中草药的作用机制多种多样,可针对心血管疾病的关键风险因素和途径。虽然前景广阔,但仍需通过精心设计的试验进一步研究其临床效用,以确定其安全性和有效性,为心血管疾病的综合管理方法铺平道路。在预防和治疗心血管疾病的过程中,医疗服务提供者和患者应在知情的情况下讨论在使用传统疗法的同时使用草药干预的问题。
{"title":"A Systematic Review of Herbal Interventions for the Management of Cardiovascular Diseases.","authors":"Ankita Wal, Neha Verma, Senthil Kumar Balakrishnan, Vinod Gahlot, Sumeet Dwivedi, Pankaj Kumar Sahu, Mohammad Tabish, Pranay Wal","doi":"10.2174/011573403X286573240422104647","DOIUrl":"10.2174/011573403X286573240422104647","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular diseases represent a significant global health burden, necessitating diverse approaches for effective management. Herbal interventions have gained attention as potential adjuncts or alternatives to conventional therapies due to their perceived safety and therapeutic potential. This structured abstract provides a comprehensive review of herbal interventions for the management of CVDs, summarising key findings, mechanisms of action, and clinical implications.</p><p><strong>Objective: </strong>This systematic review aims to evaluate the impact of various herbal interventions employed for managing cardiovascular diseases.</p><p><strong>Method: </strong>We conducted an extensive literature search across electronic databases, including PubMed, Scopus, and Web of Science, from inception to 2022. Studies were included if they investigated the use of herbal remedies for preventing or treating CVDs. Data extraction and synthesis focused on botanical sources, active compounds, mechanisms of action, and clinical outcomes.</p><p><strong>Result: </strong>Numerous herbal interventions have demonstrated promising cardiovascular benefits. A number of medicinal herbs well identified to treat CVD are <i>Moringaoleifera, Ginseng, Ginkgo biloba, Celosia argentea, Gongronematrifolium, Gynostemmapentaphyllum, Bombaxceiba, Gentianalutea, Allium sativum, Crataegus spp, Curcuma longa, Camellia sinensis, and Zingiber officinale</i>. Mechanistic insights reveal that herbal interventions often target multiple pathways involved in CVD pathogenesis. These mechanisms encompass anti-inflammatory, antioxidant, anti-thrombotic, anti-hypertensive, and lipid-lowering effects. Additionally, some herbs enhance endothelial function, promote nitric oxide production, and exert vasodilatory effects, contributing to improved cardiovascular health. Clinical studies have provided evidence of the efficacy of certain herbal interventions in reducing CVD risk factors and improving patient outcomes. However, more rigorous, large-scale clinical trials are needed to establish their long-term safety and effectiveness. It is crucial to consider potential herb-drug interactions and standardise dosages for reliable therapeutic outcomes.</p><p><strong>Conclusion: </strong>This comprehensive review highlights the potential of herbal interventions as valuable adjuncts or alternatives for managing cardiovascular diseases. Herbal remedies offer diverse mechanisms of action, targeting key CVD risk factors and pathways. While promising, their clinical utility warrants further investigation through well-designed trials to establish their safety and efficacy, paving the way for integrated approaches to cardiovascular disease management. Healthcare providers and patients should engage in informed discussions about the use of herbal interventions alongside conventional therapies in the context of CVD prevention and treatment.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e030524229664"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Cardiology Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1